Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1999 Sep 24;79(1):82–88. doi: 10.1038/sj.bjc.6690015

Pharmacodynamics of cisplatin in human head and neck cancer: correlation between platinum content, DNA adduct levels and drug sensitivity in vitro and in vivo

M J P Welters 1, A M J Fichtinger-Schepman 1, R A Baan 1, A J Jacobs-Bergmans 1, A Kegel 2, W J F van der Vijgh 3, B J M Braakhuis 4
PMCID: PMC2362173  PMID: 10408697

Abstract

Total platinum contents and cisplatin–DNA adduct levels were determined in vivo in xenografted tumour tissues in mice and in vitro in cultured tumour cells of head and neck squamous cell carcinoma (HNSCC), and correlated with sensitivity to cisplatin. In vivo, a panel of five HNSCC tumour lines growing as xenografts in nude mice was used. In vitro, the panel consisted of five HNSCC cell lines, of which four had an in vivo equivalent. Sensitivity to cisplatin varied three- to sevenfold among cell lines and tumours respectively. However, the ranking of the sensitivities of the tumour lines (in vivo), also after reinjection of the cultured tumour cells, did not coincide with that of the corresponding cell lines, which showed that cell culture systems are not representative for the in vivo situation. Both in vitro and in vivo, however, significant correlations were found between total platinum levels, measured by atomic absorption spectrophotometry (AAS), and tumour response to cisplatin therapy at all time points tested. The levels of the two major cisplatin–DNA adduct types were determined by a recently developed and improved32P post-labelling assay at various time points after cisplatin treatment. Evidence is presented that the platinum–AG adduct, in which platinum is bound to guanine and an adjacent adenine, may be the cytotoxic lesion because a significant correlation was found between the platinum–AG levels and the sensitivities in our panel of HNSCC, in vitro as well as in vivo. This correlation with the platinum–AG levels was established at 1 h (in vitro) and 3 h (in vivo) after the start of the cisplatin treatment, which emphasizes the importance of early sampling. © 1999 Cancer Research Campaign

Keywords: cisplatin, DNA adducts, head and neck cancer, platinum accumulation, cisplatin sensitivity

Full Text

The Full Text of this article is available as a PDF (83.2 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Braakhuis B. J., Ruiz van Haperen V. W., Welters M. J., Peters G. J. Schedule-dependent therapeutic efficacy of the combination of gemcitabine and cisplatin in head and neck cancer xenografts. Eur J Cancer. 1995 Dec;31A(13-14):2335–2340. doi: 10.1016/0959-8049(95)00419-x. [DOI] [PubMed] [Google Scholar]
  2. Burnouf D., Duane M., Fuchs R. P. Spectrum of cisplatin-induced mutations in Escherichia coli. Proc Natl Acad Sci U S A. 1987 Jun;84(11):3758–3762. doi: 10.1073/pnas.84.11.3758. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Eastman A. Reevaluation of interaction of cis-dichloro(ethylenediamine)platinum(II) with DNA. Biochemistry. 1986 Jul 1;25(13):3912–3915. doi: 10.1021/bi00361a026. [DOI] [PubMed] [Google Scholar]
  4. Fichtinger-Schepman A. M., van Dijk-Knijnenburg H. C., Dijt F. J., van der Velde-Visser S. D., Berends F., Baan R. A. Effects of thiourea and ammonium bicarbonate on the formation and stability of bifunctional cisplatin-DNA adducts: consequences for the accurate quantification of adducts in (cellular) DNA. J Inorg Biochem. 1995 May 15;58(3):177–191. doi: 10.1016/0162-0134(94)00045-c. [DOI] [PubMed] [Google Scholar]
  5. Fichtinger-Schepman A. M., van Dijk-Knijnenburg H. C., van der Velde-Visser S. D., Berends F., Baan R. A. Cisplatin- and carboplatin-DNA adducts: is PT-AG the cytotoxic lesion? Carcinogenesis. 1995 Oct;16(10):2447–2453. doi: 10.1093/carcin/16.10.2447. [DOI] [PubMed] [Google Scholar]
  6. Fichtinger-Schepman A. M., van Oosterom A. T., Lohman P. H., Berends F. cis-Diamminedichloroplatinum(II)-induced DNA adducts in peripheral leukocytes from seven cancer patients: quantitative immunochemical detection of the adduct induction and removal after a single dose of cis-diamminedichloroplatinum(II). Cancer Res. 1987 Jun 1;47(11):3000–3004. [PubMed] [Google Scholar]
  7. Fichtinger-Schepman A. M., van der Veer J. L., den Hartog J. H., Lohman P. H., Reedijk J. Adducts of the antitumor drug cis-diamminedichloroplatinum(II) with DNA: formation, identification, and quantitation. Biochemistry. 1985 Jan 29;24(3):707–713. doi: 10.1021/bi00324a025. [DOI] [PubMed] [Google Scholar]
  8. Fichtinger-Schepman A. M., van der Velde-Visser S. D., van Dijk-Knijnenburg H. C., van Oosterom A. T., Baan R. A., Berends F. Kinetics of the formation and removal of cisplatin-DNA adducts in blood cells and tumor tissue of cancer patients receiving chemotherapy: comparison with in vitro adduct formation. Cancer Res. 1990 Dec 15;50(24):7887–7894. [PubMed] [Google Scholar]
  9. Fisch M. J., Howard K. L., Einhorn L. H., Sledge G. W. Relationship between platinum-DNA adducts in leukocytes of patients with advanced germ cell cancer and survival. Clin Cancer Res. 1996 Jun;2(6):1063–1066. [PubMed] [Google Scholar]
  10. Gupta-Burt S., Shamkhani H., Reed E., Tarone R. E., Allegra C. J., Pai L. H., Poirier M. C. Relationship between patient response in ovarian and breast cancer and platinum drug-DNA adduct formation. Cancer Epidemiol Biomarkers Prev. 1993 May-Jun;2(3):229–234. [PubMed] [Google Scholar]
  11. Hill B. T., Shellard S. A., Fichtinger-Schepman A. M., Schmoll H. J., Harstrick A. Differential formation and enhanced removal of specific cisplatin-DNA adducts in two cisplatin-selected resistant human testicular teratoma sublines. Anticancer Drugs. 1994 Jun;5(3):321–328. doi: 10.1097/00001813-199406000-00010. [DOI] [PubMed] [Google Scholar]
  12. Johnsson A., Cavallin-Stahl E. A topographic study on the distribution of cisplatin in xenografted tumors on nude mice. Anticancer Drugs. 1996 Jan;7(1):70–77. doi: 10.1097/00001813-199601000-00008. [DOI] [PubMed] [Google Scholar]
  13. Kelland L. R., Jones M., Abel G., Valenti M., Gwynne J., Harrap K. R. Human ovarian-carcinoma cell lines and companion xenografts: a disease-oriented approach to new platinum anticancer drug discovery. Cancer Chemother Pharmacol. 1992;30(1):43–50. doi: 10.1007/BF00686484. [DOI] [PubMed] [Google Scholar]
  14. Kobayashi H., Man S., Graham C. H., Kapitain S. J., Teicher B. A., Kerbel R. S. Acquired multicellular-mediated resistance to alkylating agents in cancer. Proc Natl Acad Sci U S A. 1993 Apr 15;90(8):3294–3298. doi: 10.1073/pnas.90.8.3294. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Los G., Blommaert f. A., Barton R., Heath D. D., den Engelse L., Hanchett C., Vicario D., Weisman R., Robbins K. T., Howell S. B. Selective intra-arterial infusion of high-dose cisplatin in patients with advanced head and neck cancer results in high tumor platinum concentrations and cisplatin-DNA adduct formation. Cancer Chemother Pharmacol. 1995;37(1-2):150–154. doi: 10.1007/BF00685642. [DOI] [PubMed] [Google Scholar]
  16. Motzer R. J., Reed E., Perera F., Tang D., Shamkhani H., Poirier M. C., Tsai W. Y., Parker R. J., Bosl G. J. Platinum-DNA adducts assayed in leukocytes of patients with germ cell tumors measured by atomic absorbance spectrometry and enzyme-linked immunosorbent assay. Cancer. 1994 Jun 1;73(11):2843–2852. doi: 10.1002/1097-0142(19940601)73:11<2843::aid-cncr2820731130>3.0.co;2-d. [DOI] [PubMed] [Google Scholar]
  17. Pizao P. E., Lyaruu D. M., Peters G. J., van Ark-Otte J., Winograd B., Giaccone G., Pinedo H. M. Growth, morphology and chemosensitivity studies on postconfluent cells cultured in 'V'-bottomed microtiter plates. Br J Cancer. 1992 Oct;66(4):660–665. doi: 10.1038/bjc.1992.333. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Poirier M. C., Reed E., Litterst C. L., Katz D., Gupta-Burt S. Persistence of platinum-ammine-DNA adducts in gonads and kidneys of rats and multiple tissues from cancer patients. Cancer Res. 1992 Jan 1;52(1):149–153. [PubMed] [Google Scholar]
  19. Poirier M. C., Reed E., Shamkhani H., Tarone R. E., Gupta-Burt S. Platinum drug-DNA interactions in human tissues measured by cisplatin-DNA enzyme-linked immunosorbent assay and atomic absorbance spectroscopy. Environ Health Perspect. 1993 Mar;99:149–154. doi: 10.1289/ehp.9399149. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Reed E., Ozols R. F., Tarone R., Yuspa S. H., Poirier M. C. The measurement of cisplatin-DNA adduct levels in testicular cancer patients. Carcinogenesis. 1988 Oct;9(10):1909–1911. doi: 10.1093/carcin/9.10.1909. [DOI] [PubMed] [Google Scholar]
  21. Reed E., Parker R. J., Gill I., Bicher A., Dabholkar M., Vionnet J. A., Bostick-Bruton F., Tarone R., Muggia F. M. Platinum-DNA adduct in leukocyte DNA of a cohort of 49 patients with 24 different types of malignancies. Cancer Res. 1993 Aug 15;53(16):3694–3699. [PubMed] [Google Scholar]
  22. Schellens J. H., Ma J., Planting A. S., van der Burg M. E., van Meerten E., de Boer-Dennert M., Schmitz P. I., Stoter G., Verweij J. Relationship between the exposure to cisplatin, DNA-adduct formation in leucocytes and tumour response in patients with solid tumours. Br J Cancer. 1996 Jun;73(12):1569–1575. doi: 10.1038/bjc.1996.296. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Siddik Z. H., Boxall F. E., Harrap K. R. Flameless atomic absorption spectrophotometric determination of platinum in tissues solubilized in hyamine hydroxide. Anal Biochem. 1987 May 15;163(1):21–26. doi: 10.1016/0003-2697(87)90087-x. [DOI] [PubMed] [Google Scholar]
  24. Teicher B. A., Herman T. S., Holden S. A., Wang Y. Y., Pfeffer M. R., Crawford J. W., Frei E., 3rd Tumor resistance to alkylating agents conferred by mechanisms operative only in vivo. Science. 1990 Mar 23;247(4949 Pt 1):1457–1461. doi: 10.1126/science.247.4949.1457. [DOI] [PubMed] [Google Scholar]
  25. Tomayko M. M., Reynolds C. P. Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemother Pharmacol. 1989;24(3):148–154. doi: 10.1007/BF00300234. [DOI] [PubMed] [Google Scholar]
  26. Welters M. J., Fichtinger-Schepman A. M., Baan R. A., Hermsen M. A., van der Vijgh W. J., Cloos J., Braakhuis B. J. Relationship between the parameters cellular differentiation, doubling time and platinum accumulation and cisplatin sensitivity in a panel of head and neck cancer cell lines. Int J Cancer. 1997 May 2;71(3):410–415. doi: 10.1002/(sici)1097-0215(19970502)71:3<410::aid-ijc18>3.0.co;2-j. [DOI] [PubMed] [Google Scholar]
  27. Welters M. J., Maliepaard M., Jacobs-Bergmans A. J., Baan R. A., Schellens J. H., Ma J., van der Vijgh W. J., Braakhuis B. J., Fichtinger-Schepman A. M. Improved 32P-postlabelling assay for the quantification of the major platinum-DNA adducts. Carcinogenesis. 1997 Sep;18(9):1767–1774. doi: 10.1093/carcin/18.9.1767. [DOI] [PubMed] [Google Scholar]
  28. Yarema K. J., Lippard S. J., Essigmann J. M. Mutagenic and genotoxic effects of DNA adducts formed by the anticancer drug cis-diamminedichloroplatinum(II). Nucleic Acids Res. 1995 Oct 25;23(20):4066–4072. doi: 10.1093/nar/23.20.4066. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. van Dongen G. A., Braakhuis B. J., Leyva A., Hendriks H. R., Kipp B. B., Bagnay M., Snow G. B. Anti-tumor and differentiation-inducing activity of N,N-dimethylformamide (DMF) in head-and-neck cancer xenografts. Int J Cancer. 1989 Feb 15;43(2):285–292. doi: 10.1002/ijc.2910430221. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES